Infectious Disease Control
CGTN: 'New Approaches': How China stepped up its COVID-19 treatments
BEIJING, Dec. 21, 2022 /PRNewswire/ -- China has been racing against the clock in developing COVID-19 drugs while promoting vaccination – one for saving lives and the other for providing broad protection. While the stringent COVID-19 containment measures of the past three years helpedChina evade...
2022-12-21 18:51
3094
CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation
BEIJING, Dec. 20, 2022 /PRNewswire/ -- China now has been enhancing its COVID-19 vaccination as a priority especially among the vulnerable groups such as elders to further cement its protection for people against the virus. This strategy is becoming more prominent as the country has loosened up i...
2022-12-20 22:53
3494
CGTN: New Approaches: Why China is easing its COVID-19 curbs now
BEIJING, Dec. 20, 2022 /PRNewswire/ -- SARS-CoV-2, the virus causing COVID-19, mutates constantly. Since the beginning of the pandemic three years ago, the virus has hit the world with different faces – Alpha, Beta, Delta, Gamma and then Omicron – taking away millions of lives. Wu Zunyou, chief ...
2022-12-20 10:59
2861
Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received the clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC610, fr...
2022-12-19 13:53
3564
Bioved Pharmaceuticals, Inc. announces the results of its Phase III Randomized Clinical Trial in Moderate Covid-19 with Artovid-20®, a natural plant-based oral product
SAN JOSE, Calif., Dec. 16, 2022 /PRNewswire/ -- Published Nov 25, 2022 in the highly respected peer-reviewed journal Phytotherapy Research, results show statistically significant reduction in duration of illness and severity scores of the symptoms associated with Covid-19. In addition, statistica...
2022-12-16 01:30
2613
Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes
GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of$125 million aggregate principal amount of convertible...
2022-12-15 23:43
4639
International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children's Cancers
ACC, NCCN, ACS, and CHAI collaborate to launch new NCCN Harmonized Guidelines for Sub-Saharan Africa focused on pediatric cancers; available free at NCCN.org/harmonized. DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NC...
2022-12-15 14:07
2115
Stemirna receives Emergency Use Authorization from Laos for its proprietary mRNA vaccine
SHANGHAI, Dec. 14, 2022 /PRNewswire/ -- On December 8, 2022, Stemirna Therapeutics Co., Ltd. (Stemirna), a Chinese biotech startup specialized inmRNA technology-based drug development, received an Emergency Use Authorization (EUA) from the Food and Drug Department under the Ministry of Health of ...
2022-12-15 12:27
5347
CGTN: How China strengthens vaccine cooperation to battle COVID-19
BEIJING, Dec. 15, 2022 /PRNewswire/ -- Since the outbreak of COVID-19, the world has raced against time, battling the pandemic as it wreaked havoc across the globe. Developing safe and effective vaccines is one of the most crucial steps in the fight against the virus. For the last nearly three y...
2022-12-15 09:16
3409
Novavax Announces Proposed $125 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its c...
2022-12-15 05:39
4472
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...
2022-12-14 15:17
4926
CGTN: 'New Approaches': Hospitals gear up to prioritize COVID-19 patients
BEIJING, Dec. 14, 2022 /PRNewswire/ -- To echo China's new guidelines for COVID-19 prevention and control, local governments and hospitals across the country have been optimizing medical services and the allocation of medical resources to face a likely surge in patients and take better care of th...
2022-12-14 12:36
3229
Fosun International Receives "ESG Leading Enterprise Award" and "ESG Leading Social Initiative Award" from Bloomberg Businessweek/Chinese Edition
HONG KONG, Dec. 14, 2022 /PRNewswire/ -- On 12 December 2022, the results of the fourth ESG Leading Enterprise Awards 2022, which was organized by the Chinese Edition of Bloomberg Businessweek in partnership with Deloitte, one of the world's largest accounting firms, and with the support from Inv...
2022-12-14 11:09
4017
CGTN: The Chinese are sharing their COVID experiences as policy optimized
BEIJING, Dec. 13, 2022 /PRNewswire/ -- Vincent Zhong is a Chinese digital gadget YouTuber with more than 372,000 followers. Aside from smartphones, earbuds and laptops, Zhong recently unboxed a special object: COVID-19. "I'm screwed," Zhong said in a video showing a positive COVID test result on ...
2022-12-13 12:49
2872
CGTN: Infrastructure, vaccines and space: China-Arab sci-tech cooperation
BEIJING, Dec. 12, 2022 /PRNewswire/ -- Under the Belt and Road Initiative (BRI),
China-Arab cooperation in the fields of infrastructure, space and health has
been continuously developed in a sustainable manner.
2022-12-12 15:39
3359
China further optimizes COVID-19 response with new measures
BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from People's Daily: Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by the country on further optimizing the COVID-19 response, so as to contain the epidemi...
2022-12-12 11:38
2339
China recalibrates its COVID-19 response strategy
BEIJING, Dec. 12, 2022 /PRNewswire/ -- After months of lining up every two to three days to take a nucleic acid test at temporary testing stations dotting the urban landscape, many Chinese residents were pleasantly surprised to learn onDecember 7 that they would no longer be required to take the ...
2022-12-12 10:22
2215
Asia embraces the dawn
HONG KONG, Dec. 10, 2022 /PRNewswire/ -- A photo exhibition that captures the changes in Asian people's daily lives under the COVID-19 pandemic and encourages people to move forward opened inHong Kong on Friday. Co-organized by China Daily and the Asia News Network, the Changing Asia – New Norma...
2022-12-10 00:31
9704
Australian Scientists Honoured with the Grand Hamdan Award
DUBAI, UAE, Nov. 25, 2022 /PRNewswire/ -- The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place on 23rd of November the Museum of the Future. The Award celebrated its 12th term (2021-2022) and 22nd year, in the presence of SheikhRas...
2022-11-25 10:39
3623
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...
2022-11-23 19:43
4285
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 277 media titles]
2025-12-26 12:55Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 263 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54Sobot Shines in G2 Winter 2026: A New Benchmark in AI Customer Service
[Picked up by 252 media titles]
2025-12-24 10:00